Evidencia actualizacion en la práctica ambulatoria
November 1, 2007
David Orozco
2 20 00 07 7 EVIDENCIA -Actualización en la Práctica Ambulatoria 145 Objetivo Revisar sistemáticamente la evidencia científica acerca del uso de cannabis y la ocurrencia de episodios psicóticos o afectivos que perduran más allá de la intoxicación aguda. Fuente y selección de datosLos autores buscaron en las bases de datos Medline, Embase, CINAHL, PsycINFO, ISI Web of Knowledge
The Australian and New Zealand journal of psychiatry
November 2007
Carissa M Coulston, Michael Perdices, Christopher C Tennant
Research on the neuropsychology of substance use in schizophrenia has been steadily growing over the past decade. However, significant gaps remain in the knowledge of individual substances and their relationship to cognition in the schizophrenia spectrum disorders. Approximately 65 studies to date have directly examined this relationship. Of these, approximately 20 have focused on nicotine, 15...
Advances in Psychiatric Treatment
October 31, 2007
John Macleod
6 citations
Evidence for the effectiveness of treatment or secondary prevention of psychotic illness such as schizophrenia is often disappointing. This situation reflects our limited understanding of the aetiology of psychosis. There is good evidence that both genetic and environmental factors are implicated but the precise identity of these is unclear. Cannabis use is one candidate as a possible,...
PLoS Biology
October 2007
Krisztina Monory, Heike Blaudzun, Federico Massa et al.
Marijuana and its main psychotropic ingredient Delta(9)-tetrahydrocannabinol (THC) exert a plethora of psychoactive effects through the activation of the neuronal cannabinoid receptor type 1 (CB1), which is expressed by different neuronal subpopulations in the central nervous system. The exact neuroanatomical substrates underlying each effect of THC are, however, not known. We tested locomotor,...
The Neuroscientist
October 2007
Linda Chang, Edward P Chronicle
Cannabis remains the most widely used illegal drug in the United States. This update examines the available literature on neuroimaging studies of the brains of cannabis users. The majority of studies examining the acute effects of delta-9-tetrahydrocannabinol (THC) administration used PET methods and concluded that administration of THC leads to increased activation in frontal and paralimbic...
Indian Journal of Psychiatry
October 2007
Vani Kulhalli, Mohan Isaac, Pratima Murthy
The correlation between cannabis and negative mental health outcomes has been unequivocally established. Nevertheless, there is still a great need to research different dimensions of cannabis-related disorders, among which the study of cannabis-related psychosis is very important. There is a dearth of research regarding phenomenology and effect of abstinence, particularly from India. This study...
Biochemical and Biophysical Research Communications
September 28, 2007
Futoshi Taura, Emi Dono, Supaart Sirikantaramas et al.
Delta(1)-Tetrahydrocannabinolic acid (THCA) synthase is the enzyme that catalyzes the oxidative cyclization of cannabigerolic acid into THCA, the acidic precursor of Delta(1)-tetrahydrocannabinol. We developed a novel expression system for THCA synthase using a methylotrophic yeast Pichia pastoris as a host. Under optimized conditions, the transgenic P. pastoris secreted approximately...
Behavioural Pharmacology
September 2007
Young May Cha, Katherine H Jones, Cynthia M Kuhn et al.
Like other recreational drugs, cannabinoids may produce different effects in men and women. In this study we measured the effects of delta9-tetrahydrocannabinol (THC) on spatial learning in two groups that are underrepresented in drug research--females and adolescents. In the first experiment, adolescent (postnatal day 30) and adult (postnatal day 70) rats of both sexes were treated...
Neuropsychopharmacology
September 2007
Tiziana Rubino, Mariaelvina Sala, Daniela Viganò et al.
We investigated the effect of low doses of intraperitoneal Delta(9)-tetrahydrocannabinol (THC) on anxiety behavior in rats using the elevated plus maze (EPM). An anxiolytic effect was obtained in a range of doses between 0.075 and 1.5 mg/kg, the 0.75 dose being the most effective. Pretreatment with the CB1 receptor antagonist AM251 fully reversed THC's effect, suggesting CB1 receptors were...
Psychopharmacology
September 2007
Stephen A Varvel, Billy R Martin, Aron H Lichtman
Recent evidence has provided support for the incentive-sensitization model of addiction, where repeated stimulation of neural reward circuits leads to a long-lasting sensitization of mesolimbic dopaminergic activity. This phenomenon has been demonstrated with many drugs of abuse, most often by measuring progressively increased activating effects of drugs on locomotor activity, thought to...